advertisement
Advertisement (image not found)

Drug Discovery

Page
12345»

Nanotube Therapy Takes Aim At Breast Cancer Stem Cells

Wake Forest Baptist Medical Center researchers have again proven that injecting...

Friday, February 10, 2012 Source: Wake Forest Baptist Medical Center

Largest-Ever Gene Study Of Type 2 Diabetes Finds Variants Across Many Ethnic Groups

The largest genetics study to date of type 2 diabetes (T2D) has identified new...

Friday, February 10, 2012 Source: Children's Hospital of Philadelphia

Genetic Risks For Type 2 Diabetes Span Multiple Ethnicities

A recent large and comprehensive analysis of 50,000 genetic variants across...

Friday, February 10, 2012 Source: Cell Press

Georgia Tech Chooses TAP’s Micro Bioreactor For Novel Stem Cell Research

Cambridge, UK: TAP Biosystems, a leading supplier of innovative automation and...

Friday, February 10, 2012 Source: TAP Biosystems

Boston University Research Suggests New Pathways For Cancer Progression

– Observing that certain cancer cells may exhibit greater flexibility than normal...

Thursday, February 09, 2012 Source: Boston University College of Engineering

New Target For Alzheimer's Drugs

RIVERSIDE, Calif. — Biomedical scientists at the University of California, Riverside...

Thursday, February 09, 2012 Source: University of California - Riverside

Flipping A Light Switch In The Cell: Quantum Dots Used For Targeted Neural Activation

WASHINGTON, Feb. 8—By harnessing quantum dots—tiny light-emitting semiconductor...

Thursday, February 09, 2012 Source: Optical Society of America

Research Team Delves Into The Roots Of Hunger And Eating

BOSTON – Synaptic plasticity – the ability of the synaptic connections between...

Thursday, February 09, 2012 Source: Beth Israel Deaconess Medical Center

DNA Sequencing Helps Identify Cancer Cells For Immune System Attack

DNA sequences from tumor cells can be used to direct the immune system to attack...

Thursday, February 09, 2012 Source: Washington University School of Medicine

ARGEN-X ADVANCES A THIRD THERAPEUTIC ANTIBODY PROGRAM INTO PRECLINICAL DEVELOPMENT

ROTTERDAM, The Netherlands and GHENT, Belgium, February 8, 2012 /PRNewswire/ --

Wednesday, February 08, 2012 Source: arGEN-X
Page
12345»

News Search

Search News By Keywords
advertisement
Advertisement (image not found)

Email Newsletter Sign-Up

Stay updated on the latest technologies and news with Biocompare's newsletters
(See samples here)






Select All

Loading

Loading